27 Jun 2013, BioSpectrum Bureau , BioSpectrum
Singapore: Australia-based Phylogica has developed and patented an enhancement to its Phylomer peptide platform to discover more sophisticated cell-penetrating drugs to help tackle disease. Phylogica's technology identifies effective cell-penetrating peptides that can deliver targeted therapeutic drug cargos to a desired location.
Phylogica's Endosomal Escape Trap enables the efficient identification of Phylomer CPP-drug conjugates that not only deliver the therapeutic payload across the cell membrane, but also efficiently escape from the endosome so that the drug can have a therapeutic effect.
Dr Paul Watt, CEO, Phylogica, said that, "The opportunity for developing peptide-drug conjugates targeting abnormal processes that manifest within the cell is substantial, with the potential to treat an enormous variety of diseases more effectively. The vast majority of known disease targets reside inside of cells, yet we can't reach them with the next generation of molecular therapies, because of the barriers presented by cell membranes."
Dr Richard Hopkins, Phylogica's chief scientific officer, presented the ‘Endosomal Escape Trap' technology at the 23rd American Peptide Symposium in Hawaii, US, and the 8th Next Generation Protein Therapeutics Summit in California, US.